Serum YKL-40, a new prognostic biomarker in cancer patients?

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 2, 2006, Pages 194-202

  Johansen, Julia S ^a   Jensen, Benny Vittrup ^a   Roslind, Anne ^a   Nielsen, Dorte ^a   Price, Paul A ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHITINASE; GROWTH FACTOR; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADVANCED CANCER; ANGIOGENESIS; CANCER; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER SCREENING; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; IMAGING; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RETROSPECTIVE STUDY; REVIEW; SCREENING TEST; SOLID TUMOR;

AUTOANTIGENS; GLYCOPROTEINS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644782522     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0011     Document Type: Review

References (103)

1. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
2. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
3. Morrison BW, Leder P. neu and ras initiate murine mammary rumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
4. Shackelton LM, Mann DM, Millis AJT. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076-83.
5. De Ceuninck F, Pastoureau P, Bouet F, Bonnet J, Vanhoutte PM. Purification of guinea pig YKL-40 and modulation of its secretion by cultured articular chondrocytes. J Cell Biochem 1998;69:414-24.
6. Mohanty AK, Singh G, Paramasivam M, et al. Crystal structure of a novel regulatory 40 kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem 2003;278:14451-60.
7. Henrissat B, Bairoch A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem J 1993;293:781-8.
8. Aronson NN, Blanchard CJ, Madura JD. Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J Chem Int Comput Sci 1997;37:999-1005.
9. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
10. Arias EB, Verhage HG, Jaffe RC. Complementary deoxyribonucleic acid cloning and molecular characterization of an estrogen-dependent human oviductal glycoprotein. Biol Reprod 1994;51:685-94.
11. Buhi WC. Characterization and biological roles of oviduct-specific, oestrogen-dependent glycoprotein. Reproduction 2002;123:355-62.
12. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JMFG. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995;270:26252-6.
13. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996;271:19415-20.
14. Saito A, Ozaki K, Fujiwara T, Nakamura Y, Tanigami A. Isolation and mapping of a human lung-specific gene, TSA1902, encoding a novel chitinase family member. Gene 1999;239:325-31.
15. Guoping C, Fan P, Jingxi S, Xiaoping L, Shiqin J, Yuri L. Purification and characterization of a silica-induced bronchoalveolar lavage protein with fibroblast growth-promoting activity. J Cell Biochem 1997;67:257-64.
16. Boot RG, Blommaart EFC, Swart E, et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 2001;276:6770-8.
17. Jin HM, Copeland NG, Gilbert DJ, Jenkins NA, Kirkpatrick RB, Rosenberg M. Genetic characterization of the murine Ym1 gene and identification of a cluster of highly homologous genes. Genomics 1998;54:316-22.
18. Owhashi M, Arita H, Hayai N. Identification of a novel eosinophil chemotactic cytokine (ECF-L) as a chitinase family protein. J Biol Chem 2000;275:1279-86.
19. Kirkpatrick RB, Matico RE, McNulty DE, Strickler JE, Rosenberg M. An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 1995;153:147-54.
20. Kawamura K, Shibata T, Saget O, Peel D, Bryant PJ. A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Development 1999;126:211-9.
21. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221-5.
22. Rehli M, Niller H-H, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003;278:44058-67.
23. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003;278:37753-60.
24. Houston DR, Recklies AD, Krupa JC, van Aalten DMF. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003;278:30206-12.
25. Henrissat B, Davies G. Structural and sequence-based classification of glycoside hydrolases. Curr Opin Struct Biol 1997;7:637-44.
26. Renkema GH, Boot GR, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lecrin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-9.
27. Millis AJT, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986;127:366-72.
28. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJT. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73.
29. Lal A, Lash AE, Altschul SF, et al. A public database for gene expression in human cancers. Cancer Res 1999;59:5403-7.
30. Markert JM, Fuller CM, Gillespie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001;5:21-33.
31. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-8.
32. Shostak K, Labunskyy V, Dmitrenko V, et al. HC gp-39 gene is upregulated in glioblastoma. Cancer Lett 2003;198:203-10.
33. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65:1678-86.
34. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001;98:15044-9.
35. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 2003;162:781-92.
36. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PEG. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005;96:183-90.
37. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differentiated diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005;11:2258-64.
38. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005;11:3326-34.
39. Roslind A, Johansen JS, Junker N, et al. YKL-40 expression in breast cancer. Meeting Proceedings of the American Society for Clinical Oncology, ASCO 2005;23:abstract 9665.
40. Johansen JS, Hansen U, Christensen IJ, Garbarsch C, Price PA, Nielsen HJ. YKL-40 protein expression in cancer cells and macrophages in colorectal cancer. Meeting Proceedings of the American Society for Clinical Oncology, ASCO 2005;23:abstract 3718.
41. Junker N, Johansen JS, Andersen CB, Kristjansen PEG. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-31.
42. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46-54.
43. Verhoeckx KCM, Bijlsma S, de Groene EM, Witkamp RF, van der Greef J, Rodenburg RJT. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004;4:1014-28.
44. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110:351-60.
45. Hashimoto S, Suzuki T, Dong H-Y, Yamazaki N, Matsushima K. Serial analysis of gene expression in human monocytes and macrophages. Blood 1999;94:837-44.
46. Suzuki T, Hashimoto S, Toyoda N, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000;96:2584-91.
47. Krause SW, Rehli M, Kreutz M, Schwarzfisher L, Paulauski JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996;60:540-5.
48. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2001;44:826-37.
49. Stokes DG, Liu G, Coimbra IB, Piera-Velazquez S, Crowl RM, Jimenez SA. Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum 2002;46:404-19.
50. Imabayashi H, Mori T, Gojo S et al. Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profiling by large-scale cDNA analysis. Exp Cell Res 2003;288:35-50.
51. Millis AJT, Hoyle M, Reich E, Mann DM. Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem 1985;260:3754-61.
52. Nishikawa KC, Millis AJT. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79-87.
53. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990;268:265-8.
54. Dasuri K, Antonovici M, Chen K, et al. The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res Ther 2004;6:R161-8.
55. Baeten D, Boots AMH, Steenbakkers PGA, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium. Correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000;43:1233-43.
56. Volck B, Johansen JS, Stoltenberg M, et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001;9:203-14.
57. Boot RG, van Achterberg TAE, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19:687-94.
58. Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 1999;42:2624-30.
59. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology 2003;38:577-88.
60. Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
61. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926-31.
62. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002;365:119-26.
63. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-α. Biochem J 2004;380:651-9.
64. Trikha M, Corringham R, Klein B, Rossi J-F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
65. Meyer MF, Kreil G. Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan. Proc Natl Acad Sci U S A 1996;93:4543-7.
66. Semino CE, Specht CA, Raimondi A, Robbins PW. Homologs of the Xenopus developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod-like chitin oligosaccharides during early embryogenesis. Proc Natl Acad Sci U S A 1996;93:4548-53.
67. Varki A. Does DG42 synthesize hyaluronan or chitin? A controversy about oligosaccharides in vertebrate development. Proc Natl Acad Sci U S A 1996;93:4523-5.
68. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;44:509-16.
69. Mahaney MC, Czerwinski SA, Rogers J. Genetic effects on serum levels of human cartilage glycoprotein-39 (YKL-40) in a pedigreed baboon model for age-related changes and pathology in bone [abstract no SA121]. Am Soc Bone Miner Res 1998.
70. Register TC, Carlson CS, Adams MR. Serum YKL-40 is associated with osteoarthritis and atherosclerosis in nonhuman primates. Clin Chem 2001;47:2159-61.
71. Høgdall EVS, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Høgdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000;60:247-52.
72. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
73. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999;38:618-26.
74. Vos K, Steenbakkers P, Miltenburg AMM, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000;59:544-8.
75. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999;180:1722-6.
76. Kronborg G, Østergaard C, Weis N, et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated to the outcome of the disease. Scand J Infect Dis 2002;34:323-6.
77. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003;18:287-93.
78. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003;38:599-605.
79. Tran A, Benzaken S, Saint-Paul M-C, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989-93.
80. Nøjgaard C, Johansen JS, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-86.
81. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
82. Atkinson AJ, Jr. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
83. Johansen JS, Cintin C, Jørgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995;31A:1437-42.
84. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494-9.
85. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95:267-74.
86. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I and YKL-40 in patients with metastatic prostate carcinoma. Prostate. In press.
87. Dehn H, Høgdall EVS, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 2003;82:287-93.
88. Geertsen P, Johansen JS, von der Maase H, Jensen BV, Price PA. High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with high-dose continuous intravenous infusion of interleukin-2. Meeting Proceedings of American Society for Clinical Oncology ASCO 2003;22:abstract 1603.
89. Høgdall EVS, Johansen JS, Kjaer SK, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1535-8.
90. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9:501-12.
91. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003;80:15-21.
92. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
93. Schmidt H, Johansen JS, Gehl J, Geertsen P, Fode K, von der Maase H. Elevated serum level of YKL-40 in an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. In press.
94. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Eng J Med 1986;315:1650-9.
95. Gregoire M, Lieubeau B. The role of fibroblasts in tumor behavior. Cancer Metastasis Rev 1995;14:339-50.
96. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-39.
97. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
98. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev 2004;4:71-8.
99. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
100. Werner M, Faser C, Silverberg M. Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma. Clin Chem 1993;39:2386-96.
101. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
102. Hayes DF. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Recent Results Cancer Res 1998;152:71-85.
103. Royston P. Constructing time-specific reference ranges. Stat Med 1991;10:675-90.